Quick Answer
TG THERAPEUTICS, INC. reported Operating Income Loss of $123.32 million for the year ending 2025.
- TG THERAPEUTICS, INC. showed an increase of +194.1% in Operating Income Loss from 2024 to 2025.
- This data is from TG THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), TG THERAPEUTICS, INC.'s Operating Income Loss has grown by 14,082.7%.
- Historical annual values: Fiscal year 2025: $123.32 million | Fiscal year 2024: $41.93 million | Fiscal year 2023: $20.63 million | Fiscal year 2022: -$218.32 million | Fiscal year 2021: -$344.77 million | Fiscal year 2020: -$273.59 million | Fiscal year 2019: -$169.06 million | Fiscal year 2018: -$174.40 million | Fiscal year 2017: -$118.71 million | Fiscal year 2016: -$78.97 million | Fiscal year 2015: -$63.18 million | Fiscal year 2014: -$55.72 million | Fiscal year 2013: -$22.97 million | Fiscal year 2012: -$26.90 million | Fiscal year 2011: -$882.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: